Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 18Dermatologic 8Thoracic 6Breast 5NET 2Head & Neck 2Gynecologic 2Gastrointestinal 2Endocrine 2Other solid neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Merkel Cell 2Carcinoma 1

Interventions

lutetium Lu 177 dotatate 13Specimen Handling 8Magnetic Resonance Spectroscopy 8Everolimus 8cabozantinib 6pembrolizumab 5Nivolumab 4olaparib 3lenvatinib 3X-Rays 3Lutetium-177 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2avelumab 2amino-acid, glucose, and electrolyte solution 2Sunitinib 2Radiotherapy 2Phantoms, Imaging 2Octreotide 2Ipilimumab 2Fluorodeoxyglucose F18 2Etoposide 2Cyclophosphamide 2Cisplatin 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2telotristat ethyl 1surufatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
avelumab × NET × 90 days × Clear all
NCT04291885 2026-04-09

I-MAT

Melanoma and Skin Cancer Trials Limited

Phase 2 Active not recruiting
122 enrolled
DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡